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Serum IgG immunoglobulin fractions from human subjects 
hyposensitized to poison ivy /oak by oral administration of 
urushiol suppressed the induction of delayed-type hypersensi-
tivity (DTH) responses in mice to this hapten. This suppres-
sive activity was hapten specific because it did not modify 
DTH responses to dinitrofluorobenzene (DNFB). Absorp-
0 raJ hyposensitization is a well-known technique by w hich the reactivity of sensitized humans to alkyl-catechols in urushiol, the active hapten in poison oakj ivy, ca n be reduced by daily oral administra-tion of increasing amounts of urushiol over a 3-6-
month period. The subject then requires a larger amount of urushiol 
m elicit the sa me patch test response. This hyposensitization, which 
lasts 6- 12 months, decreases the incidence of poison oak dermatitis 
in treated individuals over a season's exposure [1 ,2] . A murine model 
has been used to study DTH reactions to urushiol. The response, 
which is hapten-specific and T -cell mediated, is monitored by mea-
ruring the extent of ear swelling following urushiol chall enge on 
the ears of sensitized mice. It can be inhibited by IgG fractions from 
sensitized mice refractory to challenge, and the inhibition is elimi-
nated by absorption with lymph node cells from urushiol immune 
animals, suggesting it is mediated by anti-idiotypic antibodies [3,4] . 
Anti-idiotyl?ic antibodies regulate the immune response to haptens 
at the B- [5J or T-celllevel (5 -9]. They usually appear late in the 
course of a normal immune DTH response and are temporarily 
associated with a decreased response to antigen challenge (3 , 10, 11]. 
To de termine if oral hyposensit.jzation in humans is mediated by 
antibodies, serum lgG fractions were obtained from human subj ects 
pre- and post-hyposensitization with urushiol and administered to 
mice, which were then tes ted for their ability to be sensitized to the 
alky !catechol. 
MATERIALS AND METHODS 
Sensitization and Challenge to Urushiol in Mice These pro-
cedures have been described previously (3] . In brief, sex and age 
Manuscript received January 19, 1990; accepted for publication February 
20, 1990. 
This work was supported by National Institutes of Health grants A1-
14752 and Al-129457 and the Food and Drug Administration grant 223-
77-120 1. 
Reprint reques ts to: Dr. Vera Byers, Department of Dermatology, Box 
0536, Univcrsiry of California, San Francisco, CA 94143-0536. 
Abbreviations: 
DNFB: dinitrofluorobenzene 
DTH: delayed-type hypersensitivi ty 
LNC: lymph node cells 
U ru: urushiol 
tion of human serum with lymph node cells from urushiol-
sensitized but not DNFB-sensitized mice removed the sup-
pressive activity, suggesting that anti-idiotypic antibodies 
reacting with T-cell receptors are involved. J l11 vest Derma to! 
95:363-365, 1990 
matched female BALB/c mice 6-10 weeks of age (Simonsen Labo-
ratories, Gilroy, CA) were sensitized by abdominal painting with 
2.5 mg urushiol (Dr. H . Baer, NIH, Bethesda, MD) in 100 ,ul of 
acetone. Four days later the animals were challenged with urushiol 
(50 ,ug in 10 ,ul acetone) or with 0.5 mg of 2,4-dinitrofluoroben-
zene (DNFB, Aldrich Chemical Co., Milwaukee, WI) in 100 ,ul of 
a 4: 1 acetone : olive oil solution applied to both sides of the right 
ear. Ear thickness was measured with a Starrett engineering microm-
eter (Athol, MA), 48 and 72 h after challenge. Results are expressed 
as the difference in ear thickness between the challenged and the 
non-challenged ear, obtained for each group of six to eight mice. 
Values of each treatment group were compared using the Student t 
test at the 0.05 level of significance. N egative controls consisted of 
incremental ear swelling in non-sensitized mice painted on the ear 
and measured 48 and 72 h later. 
Preparation of Lymph Node Cell Suspensions Lymph nodes 
from the inguinal region of normal or sensitized mice (taken 4 d 
after abdominal painting with urushiol ofDNFB) were excised and 
immediately immersed at 37oC in RPM! 1640 supplemented with 
L-glutamine and 5% fetal calf serum (complete RPMI 1640). Adi-
pose tissue was removed and the nodes were blended by hand for 
15 sin a glass T eflon Potter-Elvehjem homogenizer using a loose-
fitting plunger with 3 ml complete RPMI 1640. The suspensions 
were washed 3 times with complete RPMI 1640 at 37 °C, and the 
pellets were resuspended in 2 ml complete RPMI 1640 and held at 
37"C. Trypan Blue staining indicated such cells were 98% viable. 
Hyposensitization in Humans Four "exquisitely sensitive" 
human subjects were selected on the basis of their endpoint patch 
test reactivity to urushiol, which ranged from 0.01 to 0.05 ,ug of 
urushiol [1] . Urushiol extract, diluted 1:25 in ethanol (Holister-
Stier Spokane, WA), was administered orally 9- 11.5 mg/d over a 
6- 8-month period in graduated doses, as previously described [2] , 
without side effec;ts. Each subj ect was retested 5-6 months after 
initiation of the treatment and subsequently on a monthl y bas is until 
a stable response was obtained. Significant decrease in sensitivi ty 
was noted at 5-6 months after start of therapy in two of four 
subjects, and by 9- 12 months all subjects required a five- to 50-
times increase in patch tes t dose (0 .12-0.5 g) co elicit endpoint 
DTH response. Serum samples (50 ml) were obtained before (pre-
0022-202X/ 90/S03.50 Copyri ght ©1990 by The Sociery for Investigative Dennatology, Inc. 
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Table I. Suppression of Delayed-Type Hypersensitivity Response to Urushiol in Mice Treated with Serum IgG from Urushiol 
Desensitized Humans 
Incremental Ear Swelling' 
Experiment Serum Donor Time after Hyposensitization 48 h 72 h 
AE Pre-treatment 39 ± 15 66± 17 
5 months post-treatment 20 ± 11 36 ± 12 
20± 16l 9 months post-treatment 22 ± 15 
JN Pre-treatment 56± 27 41 ± 1 
- 6 months post-treatment 27 ± 18 30± 16 
17± 16l 9 months post-treatment 40± 17 
None NjN 83 ± 32 77± 22 
2 PS Pre-treatment 52± 15 71 ± 15 
6 months post-treatment 20 ± 20 35 ± 14 
12 months post-treatment 20 ± 15 11 ± i• 
BB Pre-treatment 20 ± 11 54± 1 
6 months post-treatment 15 ± 21 31 ± 11 
12 months post-treatment 4±5 14 ± 5• 
JS None (non-Urushiol sensitive) 82 ± 21 90± 26 
None N/Ab 80± 20 93± 17 
None N/A' 24 ± 10 16± 9 
• Six mice per group were treated with immunoglobulin fractions, saline, or nothing. Eight days later mice were sensitized by abdominal painting with urushiol (2.5 mg) in aceto_n<. 
Four days later mice were cha ll enged by application of urushiol (50 ,ug) in ~cctone (10 ,ul) to the right car. Ear thickness was measured after 48 and 72 h and expressed as swdlw£ 
increment (average ± SD) between painted and non-painted cars in,um. Posltlve controls were pre-treated with nothing (exp 1) or saline (exp 2). Negative controls were ear patnttd 
onl y. 
b Pos iti ve conrrol. 
' Negat ive control. No sensitization. The incremental car swelling rel:'resents ~he non-specific irritant action of urushiol. 
J As co mpared to positive control, p < 0.05 by Student t test, p value IS two tailed. 
' As compared to positive control p < 0.01. 
treatment sera) and then at intervals after initiation of oral hyposen-
sitization (post- treatment sera) and stored at - 20 • C. 
Preparation and Assay of IgG Fractions from Human 
Sera Each serum (10 ml) was dialyzed (2 X 1 l) for 24 hat 4•c 
against the column elution buffer, which was composed of 0.02 M 
Tris-HC l, pH 8.0, contammg 0.028 M NaCl and 0.02% NaN3 , 
then chromatographed on a prewashed (10 column bed volumes) 
DEAE Affi-Gel Blue (BioRad) column (15 X 100 mm). The 280-
nm absorbing lgG containing fractions eluting in the first peak were 
pooled and dialyzed against 0.9% NaCl (2 X ll) then concen~r~t~d 
on a disposable membrane concentrator (Amtcon} to the mltlal 
serum volume. Protein content (12-30 mg/ml) was estimated by 
the Bradford method [12] . 
Pre-treatment of Mice Anesthetized mice were injected on day 
1 in the retroorbital plexus of the eye with 0.5 ml of each of the 
human IgG fractions. These were taken from hyposensltlze_d su?-
j ccts pre- and post-treatment, and from a subject born and ra1sed 111 
Europe , where poison oak/ivy does not grow (non-tmm_une seru1~). 
Control groups of mice were injected with normal sal me, or With 
nothing. Subsequ entl y (day 8), all mice were painted on the abdo-
men with either urushiol or DNFB and then challenged With uru-
shiol or DNFB on day 12, 4 d after attempted sensitization. The 
ex tent of immune response was measured by increase Ill ear cluck-
ness. 
RESULTS 
Suppression of Murine Delayed-Type Hypersensitivity Re-
sponses by Serum IgG Fractions from Human H_ypo~ensi­
tized Donors DTH responses to urushiol and DNFB 111 mtce are 
suppressed by pretreatment with serum IgG fractions from _mice 
rendered tolerant to the haptens administered 8 d prior to senstt!za-
tion [4) . This murine system was used to determine if human lgG 
immunoglobulins from urushiol hyposensitized donors (AE, JN, 
PS, and BB) also suppress the murine DTH response to urushiol 
(Table 1). Serum IgG fractions from all four donors suppressed uru-
shiol induced DTH responses over and above that seen in pre-treat-
ment sera after urushiol hyposensitization. In comparison, serum 
IgG fraction from an individual (JS) not sensitized to urushiol di 
not influence DTH responses. Maximal suppressive effects wert 
obtained 1 -4 months after serum donors were last exposed to uru-
shiol. Significant suppression was also noted in serum IgG fraction; 
from urushiol sensitized donors prior to treatment. This sugges!S 
that urushiol sensitization itself leads to development of serum IgG 
suppression. 
The specificity of the suppression induced by treating mice w-i 
IgG fractions from urushiol hyposensitized donors is illustrated in 
Table II. Treatment with serum lgG from donor JN (12 months 
hyposensitization) suppressed DTH responses to urushiol but di 
not affect responses following mouse sensitization to DNFB. ln th~ 
second example (Donor PS: pre-hyposensitization), again, urushi 
but not DNFB-induced DTH responses were suppressed. 
Absorption of Suppressor Antibodies by Urushiol-Sensitiz 
Murine Lymph Node Cells Serum IgG fractions from hypo-
sensitized human subjects were absorbed with murine lymph n 
Table II. Specificity of Inhibition of DTH Response to Urushi 
Incremental Ear Swelling 
Pre-treatment• 
Saline 
Serum IgG donor JN 
9 months post-hyposensitization 
Serum IgG Donor PS 
Pre-hyposensitization 
Urushiol 
Jim± so 
83 ± 32 
27± 18 
52± 15 
DNFB 
JJm±SD 
80 ± 20 
88± 19 
105 ± 21 
• Six mice were injected with lgG or saline 8 d before sensitization with urushi 
dinitrofluorobenzcnc (DNFB) and ear challenged with the same antigen 4 d l>t~r 
Incremental ear thickness was measured 48 h after challenge. 
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Table III. Removal of Activity from IgG Frac tions by 
Absorption w ith Urushiol Sensitized Murine Lym p h N ode Cell s• 
Incremental Ear Swellingb 
Pre- treatment Serum Absorbed With pm ± SD 
Donor AE 
5 months post-hypo- Nothing 20 ± 11 
sensitarion Uru-LN C 97 ± 32 
9 months pos t-hypo- Normal LN C 12 ± 7 
sensitization DNFB-LN C 18 ± 10 
Donor JN 
6 months post-h ypo- Nothing 27 ± 18 
sensitization Uru-LN C 76 ± 13 
9 months pos t-hypo- Normal LN C 18 ± 10 
sensitization ONFB-LNC 28 ± 11 
Donor PS 
Pre-hyposensitization Nothing 52± 15 
Uru-LN C 11 2 ± 13 
Sal ine Nothing 83 ± 32 
• Mice were pre-treated with saline or IgG fractions from Urushiol hyposensitized 
human donors. The ISG fractions were either not absorbed or were abso rbed with LNC 
from urushiol, DNFB, or normal unsensitizcd mice. 
' Urushiol-induced ca r swelling (increment ear swelling) read 48 h post-challenge. 
cells taken 4 d after sensitization w ith urushio l (Uru-LNC). Ab-
sorbed serum and unabsorbed serum were then inj ected into mice 
prior to urushiol sensitization. The results show that Uru-LNC 
absorption removed the serum fac to r inhibiting urushiol-induced 
DTH responses . N o such effect was obtained when human sera 
were absorbed with normal murine LNC or LNC from mice sensi-
tized ro DNFB (Table III) . 
DISC USSION 
One pathway for inducing antigen- o r hapten-specific tolerance in 
naive animals involves administration of antibody [13 -15]. Several 
mechanisms have been proposed for this effect, including blocking 
antigenic determinants from recognition by immunocompetent 
cells [16] and eliminating antigen [17] and idiotype-anti-idiotype 
interac tions (18 ,19] . The present inves tigations were initiated to 
determine the effect of serum IgG immunoglobulins from urushiol 
hyposensitized human donors on DTH responses induced by this 
hapten in mice. These experiments showed that the serum immuno-
globulin fractions administered to mice before urushiol treatment 
prevented sensitization. This effect was specific in that serum Ig 
transfer did not suppress se nsitization to DNFB . The suppressive 
factor in the serum IgG immunoglobulin could be absorbed by 
lymph node cells from urushiol sensitized mice but not by lymph 
node cells from non-sensitized mice or mice sensitized 
to DNFB. 
The suppressive factor is IgG, specific for urushiol , and could be 
either anti-urushio l antibody (ab 1) or anti-idio typic antibody (ab2). 
It has been reported that antibody can block sensitiza tion if g iven 
shorrly before or w ithin 24 h after antigen [20]. Anti-urushiol anti-
bodies could be absorbed out by lymph node cells from urushiol 
sensitized animals if the antigen used fo r sensitization still remained 
bound to th e cell s used fo r absorption. H owever, in view of the 
relatively short half-life of hetero logous antibody , it is unlikely that 
significant levels of antibody remain to block sensitization 8 d after 
administration. Anti-idiotypic antibodies have also been reported to 
suppress antibody responses, ·either by reacting with th e T -cell re-
ceptor [14] or inducing cellular suppression (21 ,22]. Antigen spe-
cific T cells from sensitized animals would also absorb out these 
antibodies, and they can cross strain and species barriers [21- 23]. 
Whereas eith er type of suppression might be clinically valuabl e for 
blocking urushiol reactions, anti-idiotypic antibodies potentially 
could p roduce a lo nger las ting benefit by inducin g tol erance. Addi-
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tiona] experiments are in progress to characterize the antibodies 
mediating this effect. 
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